SG11201608240RA - Macrocylic pyrimidine derivatives - Google Patents
Macrocylic pyrimidine derivativesInfo
- Publication number
- SG11201608240RA SG11201608240RA SG11201608240RA SG11201608240RA SG11201608240RA SG 11201608240R A SG11201608240R A SG 11201608240RA SG 11201608240R A SG11201608240R A SG 11201608240RA SG 11201608240R A SG11201608240R A SG 11201608240RA SG 11201608240R A SG11201608240R A SG 11201608240RA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrimidine derivatives
- macrocylic
- macrocylic pyrimidine
- derivatives
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163443 | 2014-04-03 | ||
| EP14183747 | 2014-09-05 | ||
| PCT/EP2015/057399 WO2015150555A1 (en) | 2014-04-03 | 2015-04-02 | Macrocylic pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608240RA true SG11201608240RA (en) | 2016-10-28 |
Family
ID=52781117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608240RA SG11201608240RA (en) | 2014-04-03 | 2015-04-02 | Macrocylic pyrimidine derivatives |
Country Status (21)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017219846B2 (en) | 2016-02-19 | 2021-05-13 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
| PT3416957T (pt) | 2016-02-19 | 2020-09-25 | Sprint Bioscience Ab | Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes |
| WO2018177889A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| CA3057892A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| AU2018320419B2 (en) | 2017-08-23 | 2023-09-28 | Sprint Bioscience Ab | Morpholinylpyridone compounds |
| JP7199738B2 (ja) | 2017-08-23 | 2023-01-06 | スプリント バイオサイエンス アクティエボラーグ | アザインドリルピリドンおよびジアザインドリルピリドン化合物 |
| HRP20220571T1 (hr) | 2017-08-23 | 2022-06-10 | Sprint Bioscience Ab | Spoj piridilpiridona |
| AU2018320418B2 (en) | 2017-08-23 | 2023-04-06 | Sprint Bioscience Ab | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds |
| EP4107160A1 (en) * | 2020-02-18 | 2022-12-28 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| JP2023521351A (ja) * | 2020-04-07 | 2023-05-24 | アイテオ ベルギウム エスエー | がんの治療のためのｅｎｔ阻害剤としての大環状ジアミン誘導体、及びそれとアデノシン受容体拮抗薬との組合せ |
| CN113735879B (zh) * | 2020-05-27 | 2022-05-17 | 百极弘烨（广东）医药科技有限公司 | 一种大环jak抑制剂及其应用 |
| CN113735856A (zh) * | 2020-05-29 | 2021-12-03 | 百极弘烨(南通)医药科技有限公司 | 大环jak抑制剂及其应用 |
| US20230271917A1 (en) * | 2020-07-22 | 2023-08-31 | Fog Pharmaceuticals, Inc. | Amino acids |
| WO2023046030A1 (zh) * | 2021-09-23 | 2023-03-30 | 河南晟翔医药科技有限公司 | 一种egfr小分子抑制剂、含其的药物组合物及其用途 |
| KR102613509B1 (ko) * | 2021-12-15 | 2023-12-13 | 환인제약 주식회사 | 마크로사이클릭 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신경 퇴행성 질환의 예방 또는 치료용 약학적 조성물 |
| CN117229300A (zh) * | 2023-03-12 | 2023-12-15 | 药雅科技(上海)有限公司 | Egfr抑制剂的制备及其应用 |
| WO2024078263A1 (zh) * | 2022-10-09 | 2024-04-18 | 药雅科技(上海)有限公司 | 大环杂环类化合物作为egfr抑制剂的制备及其应用 |
| WO2024094171A1 (zh) * | 2022-11-04 | 2024-05-10 | 江苏恒瑞医药股份有限公司 | 取代的氨基嘧啶类化合物、其制备方法及其在医药上的应用 |
| CN116478076A (zh) * | 2023-04-26 | 2023-07-25 | 南京优氟医药科技有限公司 | 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7151096B2 (en) * | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| PT1608374E (pt) | 2003-03-24 | 2008-12-24 | Actimis Pharmaceuticals Inc | Derivados de 2-fenoxi- e 2-fenilsulfonamida com actividade antagonista do ccr3 para o tratamento da asma e de outras desordens inflamatórias e imunológicas |
| JO2785B1 (en) | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
| DE602004023876D1 (de) | 2003-12-18 | 2009-12-10 | Janssen Pharmaceutica Nv | 3-cyano-chinolin-derivate mit antiproliferativer wirkung |
| DE602004012891T2 (de) | 2003-12-18 | 2009-04-09 | Janssen Pharmaceutica N.V. | Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel |
| MY169441A (en) | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
| JO3088B1 (ar) | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
| BRPI0612888B8 (pt) * | 2005-06-30 | 2022-12-27 | Janssen Pharmaceutica Nv | anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica |
| ES2346791T3 (es) | 2005-11-16 | 2010-10-20 | S*Bio Pte Ltd | Derivados de pirimidina ligados a heteroalquilo. |
| CA2632159A1 (en) | 2005-11-24 | 2007-05-31 | Oz Communications Inc. | Method for securely associating data with http and https sessions |
| US8338422B2 (en) | 2007-06-21 | 2012-12-25 | Janssen Pharmaceutica Nv | Indolin-2-ones and aza-indolin-2-ones |
| US8318731B2 (en) | 2007-07-27 | 2012-11-27 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
| TW200922556A (en) | 2007-08-20 | 2009-06-01 | Glaxo Group Ltd | Novel cathepsin C inhibitors and their use |
| EP2283024B1 (en) * | 2008-03-10 | 2013-05-15 | Janssen Pharmaceutica, N.V. | 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
| CA2727680A1 (en) | 2008-06-13 | 2009-12-17 | Novartis Ag | 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer |
| US8415486B2 (en) | 2009-05-28 | 2013-04-09 | Tetralogic Pharmaceuticals Corp. | IAP inhibitors |
| CN102548987B (zh) | 2009-07-14 | 2014-04-16 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的氟取代化合物及其使用方法 |
| TWI513695B (zh) | 2009-10-27 | 2015-12-21 | Merck Sharp & Dohme | （１，１，１，３，３，３－六氟－２－羥基丙－２－基）苯基衍生物 |
-
2015
- 2015-04-01 MA MA039822A patent/MA39822A/fr unknown
- 2015-04-02 NZ NZ725399A patent/NZ725399A/en unknown
- 2015-04-02 MY MYPI2016001777A patent/MY185491A/en unknown
- 2015-04-02 EA EA201692003A patent/EA031246B1/ru not_active IP Right Cessation
- 2015-04-02 WO PCT/EP2015/057399 patent/WO2015150555A1/en active Application Filing
- 2015-04-02 CN CN202111600011.XA patent/CN114213415A/zh active Pending
- 2015-04-02 PE PE2016001882A patent/PE20161362A1/es unknown
- 2015-04-02 SG SG11201608240RA patent/SG11201608240RA/en unknown
- 2015-04-02 US US15/300,956 patent/US10017509B2/en active Active
- 2015-04-02 JP JP2016560825A patent/JP6529513B2/ja active Active
- 2015-04-02 BR BR112016021982-1A patent/BR112016021982B1/pt active IP Right Grant
- 2015-04-02 MX MX2016012992A patent/MX369798B/es active IP Right Grant
- 2015-04-02 CN CN201580018080.6A patent/CN106164075B/zh active Active
- 2015-04-02 UA UAA201611005A patent/UA118219C2/uk unknown
- 2015-04-02 CA CA2942636A patent/CA2942636C/en active Active
- 2015-04-02 EP EP15713522.9A patent/EP3126364B1/en active Active
- 2015-04-02 AU AU2015239098A patent/AU2015239098B2/en active Active
- 2015-04-02 KR KR1020167028764A patent/KR102390276B1/ko active Active
- 2015-04-02 ES ES15713522.9T patent/ES2667723T3/es active Active
-
2016
- 2016-09-25 IL IL248005A patent/IL248005B/en active IP Right Grant
- 2016-09-29 CL CL2016002461A patent/CL2016002461A1/es unknown
- 2016-10-03 PH PH12016501963A patent/PH12016501963B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016012992A (es) | 2016-12-07 |
| CN106164075A (zh) | 2016-11-23 |
| MY185491A (en) | 2021-05-19 |
| PE20161362A1 (es) | 2016-12-17 |
| UA118219C2 (uk) | 2018-12-10 |
| ES2667723T3 (es) | 2018-05-14 |
| EA031246B1 (ru) | 2018-12-28 |
| CN114213415A (zh) | 2022-03-22 |
| MA39822A (fr) | 2018-02-06 |
| EP3126364B1 (en) | 2018-02-07 |
| BR112016021982A2 (enrdf_load_stackoverflow) | 2017-08-15 |
| EP3126364A1 (en) | 2017-02-08 |
| BR112016021982B1 (pt) | 2022-07-26 |
| NZ725399A (en) | 2023-01-27 |
| KR102390276B1 (ko) | 2022-04-22 |
| PH12016501963A1 (en) | 2017-01-09 |
| US20170022202A1 (en) | 2017-01-26 |
| CL2016002461A1 (es) | 2017-06-23 |
| PH12016501963B1 (en) | 2017-01-09 |
| AU2015239098A1 (en) | 2016-09-29 |
| US10017509B2 (en) | 2018-07-10 |
| IL248005B (en) | 2018-12-31 |
| CN106164075B (zh) | 2021-11-26 |
| CA2942636C (en) | 2023-03-21 |
| JP6529513B2 (ja) | 2019-06-12 |
| JP2017509687A (ja) | 2017-04-06 |
| EA201692003A1 (ru) | 2017-06-30 |
| WO2015150555A1 (en) | 2015-10-08 |
| MX369798B (es) | 2019-11-21 |
| KR20160142316A (ko) | 2016-12-12 |
| AU2015239098B2 (en) | 2019-08-01 |
| CA2942636A1 (en) | 2015-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL248005B (en) | Macrocyclic pyrimidine histories | |
| IL259169A (en) | Novel pyrazolo pyrimidine derivatives | |
| SG11201605417QA (en) | Heterocyclic compounds | |
| EP3129377A4 (en) | Mertk-specific pyrimidine compounds | |
| ZA201606768B (en) | Macrocylic pyridine derivatives | |
| IL253381A0 (en) | History of h9-pyrrolo-dipyridine | |
| PL3359543T3 (pl) | Pochodne kukurbiturylu | |
| SG11201609205WA (en) | Heterocyclyl-butanamide derivatives | |
| HUE050450T2 (hu) | Fluoralkil-fluorén-származékok | |
| PL3418273T3 (pl) | Pochodne flawaglin | |
| IL248773A0 (en) | History of naphthyridinedione | |
| IL251005B (en) | Pyrido-oxazinone derivatives | |
| SG11201803357TA (en) | Pyrimidine derivative | |
| IL248629B (en) | Substances containing diheteroaryl conjugated to cycloalkyl and their uses | |
| AP2016009506A0 (en) | Pyrimidine compound | |
| SMT201900438T1 (it) | Nuovi derivati di cyp-eicosanoide | |
| GB201414116D0 (en) | Benzodiazepine derivatives | |
| PL3119744T3 (pl) | Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu | |
| PT3154985T (pt) | Compostos antivirais | |
| GB201416351D0 (en) | Heterocyclic derivatives | |
| GB2523854B (en) | Circuitry | |
| GB201410181D0 (en) | Antiviral compounds | |
| GB201403778D0 (en) | Antiviral compounds |